AMGEN
Otezla
Otezla presented a significant improvement in the disease severity in mild-to-moderate patients, according to the Phase 3 ADVANCE trial.
In the ADVANCE trial, Otezla 30 mg showed statistically significant improvement in the static Physician's Global Assessment (sPGA) response at week 16. 21.6% of patients reached the primary endpoint versus 4.1% in the placebo arm.
The drug has demonstrated improvement in all secondary endpoints. 29% of patients on Otezla showed at least 75% improvement in BSA versus 6.1% in the placebo arm.
BMS
Deucravacitinib
BMS announced POETYK PSO-1 and POETYK PSO-2 trial results, demonstrating the superiority of deucravacitinib versus placebo and Otezla.
Deucravacitinib is an oral selective tyrosine kinase 2 (TYK2) inhibitor for treating patients with moderate-to-severe plaque psoriasis.
The primary endpoints were Psoriasis Area and Severity Index (PASI) 75 and a static Physician's Global Assessment score (sPGA 0/1) at week 16.
Results of POETYK PSO-1 trial
PASI 75 at week 16
Deucravacitinib 6 mg: 58.7%
Otezla: 35.1%
Placebo: 12.7%
PASI 75 at week 24
Deucravacitinib 6 mg: 69%
Otezla: 38.1%
Results of POETYK PSO-2 trial
PASI 75 at week 16
Deucravacitinib 6 mg: 53.6%
Otezla: 40.2%
Placebo: 9.4%
PASI 75 at week 24
Deucravacitinib 6 mg: 59.3%
Otezla: 37.8%
ELI LILLY
Olumiant
Eli Lilly presented BREEZE-AD5 Phase 3 clinical trial data and showed improvement of Olumiant versus placebo in moderate to severe atopic dermatitis patients.
Results of BREEZE-AD5 trial:
Eczema Area and Severity Index (EASI)
At week one
Olumiant: 25.3%
Placebo: 7.2%
At week 4
Olumiant: 50.9%
Placebo: 24%
Comments